Healthcare, Pharma & Life Sciences

Kazia Therapeutics Closes Oversubscribed Offering, Up to $120M Raised

Image
Kazia Therapeutics Closes Oversubscribed Offering, Up to $120M Raised

Sydney – September 06, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has closed an oversubscribed, tranched public offering that generated approximately $40 million in upfront gross proceeds, with total potential proceeds reaching approximately $120 million if milestone-linked warrants are fully exercised.

Offering priced above market with milestone-triggered warrant premiums

The combined offering price was set at $15.50 per American Depositary Share (ADS), with both warrant tranches priced at premiums to that level. Series A Warrants carry an exercise price of $17.825 per ADS, a 15% premium, tied to Kazia's Stage IV triple-negative breast cancer (TNBC) data readout expected in the second half of 2027. Series B Warrants carry an exercise price of $19.375 per ADS, a 25% premium, tied to the company's HR+/HER2- breast cancer data readout expected in the first half of 2028.

Innocan Pharma Q2 Revenue Falls 25% to $5.25M on US Tariff Uncertainty

Image
Innocan Pharma Q2 Revenue Falls 25% to $5.25M on US Tariff Uncertainty

Herzliya, Israel – September 06, 2026 -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) reported second-quarter fiscal 2026 revenue of US$5.25 million (CAD 7.3 million), a 25.06% decline from US$7.01 million in the same period last year, as shifting U.S. customs and tariff policy under the Trump administration disrupted sales.

Gross margin holds above 90% despite revenue drop

Gross profit fell 23.0% to US$4.769 million, but gross margin remained elevated at 90.8% for the three months ended September 06, 2026, up from 88.4% a year earlier. The company attributed the resilience to its direct-to-consumer model and disciplined cost structure at consumer wellness subsidiary B.I. Sky Global Ltd., which it owns 60%.

Wellinks Names Ex-Teladoc COO, UConn Health CEO to Board

Image
Wellinks Names Ex-Teladoc COO, UConn Health CEO to Board

New Haven, Conn. – September 06, 2026 -- Wellinks, a virtual-first cardiopulmonary care company, has appointed Andrew Agwunobi, MD, MBA, and Mike Waters to its Board of Directors while adding three vice presidents to its management team, the company said.

Former Teladoc COO Mike Waters joins Wellinks board with digital health portfolio

Waters, who spent more than two decades in strategic operations and previously served as Chief Operating Officer of Teladoc Health, also brings 15-plus years from Providence Health, where he was Executive Vice President and Chief Executive of its Ambulatory Care Network. He currently holds board roles across six digital health companies, including Chair positions at Ieso and Brook Health.

Lilly's Taltz-Zepbound Combo Sustains Gains at 52 Weeks

Image
Lilly's Taltz-Zepbound Combo Sustains Gains at 52 Weeks

INDIANAPOLIS – September 03, 2026 -- Eli Lilly and Company reported that combining Taltz (ixekizumab) with Zepbound (tirzepatide) sustained or deepened efficacy at 52 weeks in patients with psoriatic disease and obesity, building on statistically superior results already seen at Week 36 versus Taltz alone.

Combination therapy nearly triples complete skin clearance response rates

In the TOGETHER-PsO trial, 30.6% of patients on the combination achieved PASI 100 plus at least 10% weight loss at Week 52, compared with 4.4% on Taltz monotherapy. Complete skin clearance alone (PASI 100) was maintained by 40.5% of combination patients versus 29.1% on monotherapy.

Jazz's Ziihera Shows Significant Survival Edge Over Trastuzumab in GEA Trial

Image
Jazz's Ziihera Shows Significant Survival Edge Over Trastuzumab in GEA Trial

Dublin – September 03, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) combined with chemotherapy produced a statistically significant and clinically meaningful overall survival (OS) benefit versus trastuzumab plus chemotherapy in a second interim analysis of the Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive gastroesophageal adenocarcinoma (GEA).

OS hazard ratio for Ziihera plus chemotherapy improved versus the first interim analysis

The company said the survival advantage strengthened compared with earlier data, reinforcing Ziihera's position following its FDA approval on August 25, 2026. No new safety signals emerged relative to previously reported HERIZON-GEA-01 data or the known profiles of the individual agents.

PVA Gathers 400+ Clinicians in Las Vegas for SCI/MS/ALS Care Summit

Image
PVA Gathers 400+ Clinicians in Las Vegas for SCI/MS/ALS Care Summit

Las Vegas – September 03, 2026 -- Paralyzed Veterans of America (PVA) opened its 2026 Healthcare Summit + Expo at the Horseshoe Hotel, drawing more than 400 healthcare professionals to advance clinical care for spinal cord injury, MS, and ALS. The event runs through September 2 and features 110 speakers and 60 exhibitors, with remarks from Department of Veterans Affairs Secretary Doug Collins.

Summit connects 400 clinicians to close gaps in SCI/D care

PVA National President Robert Thomas said healthcare for veterans with traumatic spinal cord injuries and diseases like MS and ALS extends from research through rehabilitation and long-term community life. PVA, founded in 1946, is the only nonprofit Veterans Service Organization with access inside all 25 VA SCI/D Centers, a position that has shaped its 80-year investment in research, clinical education, and advocacy.

ABMS Foundation Awards $300,000 in Grants for Certification Research

Image
ABMS Foundation Awards $300,000 in Grants for Certification Research

Chicago – September 03, 2026 -- The American Board of Medical Specialties (ABMS) Research and Education Foundation (REF) has awarded $300,000 in research grants to four independent investigators for its 2026-2028 cycle, the third year of the program.

ABMS Foundation issues four $75,000 grants over two-year terms

Each recipient will receive $75,000 spread across a two-year project period, running from August 31, 2026 through August 31, 2028. The awards fund independent research into the structures, processes, and outcomes tied to physician board certification, with particular focus on continuing certification's role in patient care.

SIBIONICS Unveils AI-Powered GS3 Glucose Sensor at Melbourne Congress

Image
SIBIONICS Unveils AI-Powered GS3 Glucose Sensor at Melbourne Congress

Melbourne – September 03, 2026 -- SIBIONICS showcased its AI-driven continuous glucose monitoring (CGM) sensor, GS3, at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress held in Melbourne from August 18 to 21, using a dedicated booth, a scientific symposium and on-site interviews with credentialed diabetes educators (CDEs).

Ascletis Doses First Patient in Phase III Trial of Oral GLP-1 Pill ASC30

Image
Ascletis Doses First Patient in Phase III Trial of Oral GLP-1 Pill ASC30

Hong Kong – September 03, 2026 -- Ascletis Pharma Inc. has dosed the first participant in a global Phase III program for ASC30, an oral small molecule GLP-1 receptor agonist for chronic weight management, the Hong Kong Stock Exchange-listed biotech confirmed.

Trial enrolls 4,600 participants across three continents

The program comprises two pivotal trials, AURORA-1 and AURORA-2, spanning clinical sites in the U.S., Europe, and Canada. AURORA-1 targets participants with obesity or overweight without type 2 diabetes, while AURORA-2 enrolls those with type 2 diabetes; both trials test 20 mg, 40 mg, and 60 mg maintenance doses against placebo over 72 weeks, with the primary endpoint measuring percentage change in body weight from baseline to Week 72.

INTCO Medical H1 Revenue Jumps 40.6% on Record 107 Billion Glove Capacity

ZIBO, China – September 03, 2026 -- INTCO Medical (300677.SZ) reported first-half 2026 revenue of 6.91 billion RMB (approximately $1.03 billion), a 40.61% increase year-over-year, as the disposable glove maker expanded its annualized production capacity to 107 billion units, the largest globally.

Adjusted profit surges 165% as production scales

Net income attributable to shareholders rose 17.86% to 837.3 million RMB (approximately $124.6 million) for the six months ended June 30, 2026. Adjusted net income, excluding non-recurring gains and losses, climbed 165.00% to 1.06 billion RMB (approximately $157.7 million).